Get the Stockscreener App
5.78
0.00%
0.00
Abeona Therapeutics Inc stock is traded at $5.78, with a volume of 714.32K.
It is up +0.00% in the last 24 hours and up +8.24% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$5.78
Open:
$5.78
24h Volume:
714.32K
Relative Volume:
0.59
Market Cap:
$329.43M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
5.7962
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
+6.25%
1M Performance:
+8.24%
6M Performance:
+14.00%
1Y Performance:
-6.17%
1-Day Range:
$5.78
$5.93
1-Week Range:
$5.41
$5.93
52-Week Range:
$4.00
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.78 | 329.43M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Price-Driven Insight from (ABEO) for Rule-Based Strategy - Stock Traders Daily
ABEO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Abeona Therapeutics (ABEO) director reports bona fide 500-share gift - Stock Titan
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - The Manila Times
Abeona plans Jefferies fireside chat, Goldman investor meetings - Stock Titan
Lightning eMotors Inc. (ZEV) - Minichart
Insider Sell: Mark Alvino Sells 6,500 Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics director Mark Alvino sells $35,462 in stock By Investing.com - Investing.com South Africa
Abeona Therapeutics director Mark Alvino sells $35,462 in stock - Investing.com UK
Abeona Therapeutics (ABEO) director sells 6,500 shares in open-market trade - Stock Titan
May 2026's Top Insider-Owned Growth Companies - simplywall.st
[144] ABEONA THERAPEUTICS INC. SEC Filing - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Abeona Therapeutics (NASDAQ: ABEO) Reports $8.7 Million in Q1 Revenue as ZEVASKYN Adoption Accelerates - foreignpolicyjournal.com
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum - TipRanks
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
(ABEO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated - Zacks Small Cap Research
Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips - Investing.com
Abeona Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Abeona Therapeutics Q1 2026 earnings preview - MSN
Abeona (ABEO) director 10b5-1 open-market sale of 26,143 shares - Stock Titan
Nantahala (ABEO) reports 5.78M-share 9.99% stake; managers Harkey, Mack listed - Stock Titan
Nantahala Capital reports 3.33M shares in Abeona (ABEO) as of March 31, 2026 - Stock Titan
ABEO (Nasdaq) Form 144: Insider proposes sale; restricted awards listed - Stock Titan
Jefferies Remains a Buy on Abeona Therapeutics (ABEO) - The Globe and Mail
Abeona Therapeutics (ABEO) Gets a Buy from Oppenheimer - The Globe and Mail
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript - Sahm
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network - Sahm
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - GuruFocus
Abeona Therapeutics Signals Strong Early ZEVASKYN Launch - TipRanks
Abeona Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Abeona (ABEO) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings Call Summary | Abeona Therapeutics(ABEO.US) Q1 2026 Earnings Conference - Moomoo
Abeona Therapeutics Q1 2026: Loss Narrows to $0.30/Share - AlphaStreet
Abeona Therapeutics (ABEO) Reports Strong Q1 Earnings with Reven - GuruFocus
Abeona Therapeutics Q1 Earnings Call Highlights - sharewise.com
Abeona Therapeutics Inc. Q1 2026 Financial Report: Key Highlights, Risk Factors, and ZEVASKYN Commercialization Update - Minichart
Abeona Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Abeona Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Abeona Therapeutics Reports Q1 2026 Results: Strong ZEVASKYN Adoption, Pipeline Focus on PSMA T-Cell Therapy, and $168M Cash Position - Minichart
Earnings call transcript: Abeona Therapeutics Q1 2026 beats expectations with strong revenue - Investing.com
Earnings call transcript: Abeona Therapeutics Q1 2026 beats expectations with strong revenue By Investing.com - Investing.com South Africa
Abeona Therapeutics (ABEO) Reports Strong Q1 Revenue Growth - GuruFocus
ABEO: Q1 revenue surged on ZEVASKYN uptake; profitability targeted by June; pipeline expands to oncology - TradingView
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):